Image by Valeria GB from Pixabay

February 6, 2026 - WASHINGTON, D.C. - On Thursday, Pharmaceutical Research and Manufacturers of America (PhRMA) Deputy Vice President of Media Relations Chanse Jones issued the following statement regarding compounding:   
 
“Mass compounding of new medicines weeks after their approvals undermines the public health and the entire drug review and approval framework.   
 
"These actions also present serious patient safety concerns by flooding the market with drugs that have not been reviewed by the FDA for safety, effectiveness and quality. It’s vital for patients to know compounded drugs are not FDA-approved medicines.  
 
"The FDA and other policymakers should take immediate action to ensure the integrity of the FDA's rigorous regulatory review and approval process, the drug supply chain and decades of carefully balanced approaches to fostering innovation and generic competition.” 

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. PhRMA member companies have invested more than $850 billion in the search for new treatments and cures over the last decade, supporting nearly five million jobs in the United States.

Source: PhRMA